 - Angiotensin-converting enzyme ACE inhibitors: Patients who are currently receiving ACE inhibitors are not eligible due to the development of angioneurotic edema-type reactions in some subjects who received concurrent treatment with everolimus ACE inhibitors. At least 3 half-lives must have elapsed after the last dose of ACE inhibitors. 